London, 16 & 17 October 2006
Cytyc, World leader in women's health, (www.cytyc.com), held a two-day educational seminar in London this month, focussing on its NovaSure® endometrial ablation system.
Consultant Gynaecologists in the UK and Netherlands were invited to attend an intense programme of presentations given by keynote speakers on the detailed principles of operation and clinical evidence. Surgeons, experienced in the use of the NovaSure procedure, were specifically invited to participate in the programme, to educate other Surgeons on its safe and effective use.
In a session chaired by Adrian Lower, FRCOG Consultant Gynaecologist at Harley Street, London, eminent Gynaecologists presented a review of previously published, as well as new, clinical data related to NovaSure. Experts also provided hands-on training techniques. In total, 48 surgeons from the UK and the Netherlands attended the sessions.
The NovaSure Endometrial Ablation System is currently the most widely used endometrial ablation method in the United States and is rapidly gaining market share in the U.K. and Europe.
Approved by the U.S. FDA in September 2001, the NovaSure System works by applying a 90-second, precisely controlled dose of bipolar energy to remove the lining of the uterus. Unlike other endometrial ablation treatments, the NovaSure procedure requires no hormonal pre-treatment, which is often associated with side-effects and treatment delays, and can be performed in an outpatient setting or doctor's office at any time during the menstrual cycle, increasing flexibility for both the patient and physician.
The NovaSure System provides a safe and effective, minimally invasive outpatient alternative to hysterectomy, while avoiding the potential side effects and long-term risks of drug therapy.
Notes to editors:
For further information, please contact:
Sharon Baverstock on 01256 761937 or email: email@example.com
Cytyc Corporation is a leading women's health company that designs, develops, manufactures and markets innovative and clinically effective products that help prevent the development of disease through early detection and treatment.
Cytyc products cover a range of women's health applications, including cervical cancer screening (ThinPrep Pap Test ? & ThinPrep® Imaging System), Breast cancer risk assessment (FirstCyte?), treatment of excessive menstrual bleeding (NovaSure® Impedance Controlled Endometrial Ablation System) and treatment of breast cancer (MammoSite? Partial Breast irradiation system).
Cytyc Surgical Products, a wholly-owned subsidiary of Cytyc Corporation, manufactures and markets the NovaSure® System, an innovative endometrial ablation device to treat menorrhagia, or excessive menstrual bleeding.
Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC. ThinPrep, FirstCyte and NovaSure are registered trademarks of Cytyc Corporation.
Further information on Cytyc Corporation can be found at: www.cytyc.com
Further information on NovaSure® can be found at: www.novasure.com